Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Neurothrombectomy Devices Market $1.2 Billion by 2031

The global market for neurothrombectomy devices estimated to reach $1.2 billion by 2031, growing at a CAGR of 5.8% over the forecast period, driven by increasing prevalence of acute ischemic stroke, growing prevalence for minimally invasive procedures, aging population, and unhealthy lifestyle leading to high blood pressure, high cholesterol, obesity, and diabetes.

Global Neurothrombectomy Devices Market

The neurothrombectomy devices are intended to retrieve or destroy blood clots in the cerebral neurovasculature by mechanical (i.e., snare or suction), laser, ultrasound technologies, or combination of technologies. Acute ischemic strokes (AIS) are associated with poor outcomes and high health care burden. About 87% of all strokes are ischemic strokes, in which blood flow to the brain is blocked. Currently available neurothrombectomy devices offer intriguing treatment options in patients with acute ischemic stroke.

  • Mechanical neurothrombectomy devices offer many potential advantages over pharmacologic thrombolysis, including more rapid achievement of recanalization, enhanced efficacy in treating large-vessel occlusions (LVO), and a potentially lower risk of hemorrhagic events. Currently available neurothrombectomy devices offer intriguing treatment options in patients with acute ischemic stroke.
    • The practice of endovascular therapy has evolved dramatically over the last 10 years with randomized clinical trials investigating the benefit of thrombectomy in select patient populations based on time of presentation, imaging criteria, and procedural technique. Two emerging technologies related to the treatment of patients with ischemic stroke include the use of intracranial stents as well as various imaging techniques.

The global market for neurothrombectomy devices research report provides market size ($million 2021 to 2031), market share analysis, growth trends and forecast (CAGR%, 2024 to 2031).

The global market for neurothrombectomy devices segmented by product (clot retrievers, aspiration/suction devices, vascular snares), end user (hospital, emergency clinics, ambulatory surgical centers), and geography.

Neurothrombectomy devices are categorized into five broad classes, including clot retrievers, aspiration/suction devices, snare-like devices, ultrasonography technologies, and lasers. The various classes and devices in those classes that were identified as potentially useful for thrombus removal in the neurovasculature. Neurothrombectomy devices show great potential in improving functional outcomes and reducing mortality in patients with acute ischemic stroke, and meta-analysis confirms that successful recanalization was the most important indicator of predicting clinical benefit.

  • Among the products, the clot retrievers segment accounted for the largest share of the total neurothrombectomy devices market, owing to increasing prevalence of acute ischemic stroke and number of product launches in the recent years. Some of clot retriever devices include the Attractor-18, Catch, In-Time, MERCI, Phenox, and TriSpan devices.
    • On the other hand, the aspiration/suction devices segment predicted to witness the fastest CAGR in the coming years, due to its advantages in minimizing distal embolization of the clot, first by fragmenting the clot and then by providing negative pressure to suction its small, fragmented portions. Some of the aspiration/suction devices include the Amplatz Thrombectomy, AngioJet, NeuroJet, Oasis Thrombectomy, Penumbra System, and Vasco +35.
  • The use of first-generation thrombectomy devices, most notably the Merci Retriever system (Stryker) and the Penumbra Aspiration device (Penumbra Inc.), achieved high rates of revascularization of occluded large cerebral vessels.
    • Second-generation devices, known as stent retrievers, were therefore created with the goal of achieving faster revascularization of occluded vessels and improved rates of favorable clinical outcomes. Stent retrievers, most notably the Solitaire (Medtronic – ev3/Covidien) and the Trevo (Stryker), were shown to be superior to first-generation devices in terms of achieving higher rates of favorable clinical outcomes.
      • Moreover, several recent randomized control trials have demonstrated the superiority of medical therapy with mechanical thrombectomy using stent retrievers over medical therapy alone in achieving good clinical outcome in acute stroke patients.
  • Based on the end users, the hospitals segment dominated the global neurothrombectomy devices market. At the large hospitals, the benefit of endovascular therapy over medical therapy has been observed irrespective of clinical trial design, patient selection or procedural technique.
    • Compared to traditional open surgery, the neurothrombectomy devices provides simple wound closure procedures due to advanced designs & features and permit faster healing. Experience with endovascular thrombectomy at high volume centers provides more streamlined systems of care and is associated with higher recanalization rates.
  • However, the ambulatory surgical centers (ASCs) segment expected to grow at the fastest rate throughout the forecast period, attributed to increasing demand for minimally invasive surgical procedures, introduction of technologically advanced products.
    • The last decade has witnessed rapid and significant advancement in the treatment of acute ischemic stroke, turning it from a purely neurological disease treated with systemic thrombolytic medications into an interventional condition treated with mechanical thrombectomy and in situ vessel revascularization.

The global market for neurothrombectomy devices research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

  • In terms of geography, the Europe and North America regions registered the largest revenue segments in the global neurothrombectomy devices market.
    • Every year in the U.S. approximately 795,000 people develop a new or recurrent stroke, with 610,000 first attacks and 185,000 recurrent attacks. In developed countries, it is predicted that stroke will be accountable for 6.2% of the total burden of illness.
    • Approximately 1.1 million inhabitants of Europe suffer a stroke each year, and ischemic stroke accounted for approximately 80% of cases. The number of people living with stroke is estimated to increase by 27% between 2017 and 2047 in the European Union (EU), mainly because of population ageing and improved survival rates.

In addition, the global market for neurothrombectomy devices report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for neurothrombectomy devices and profiled in this report include Acandis GmbH, Medtronic plc, Penumbra, Inc., phenox GmbH, Stryker Corporation, and Vesalio LLC.

  • Product
    • Clot Retrievers
    • Aspiration/Suction Devices
    • Vascular Snares
  • End User
    • Hospital
    • Emergency Clinics
    • Ambulatory Surgical Centers (ASCs)
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Acandis GmbH
    • Medtronic plc
    • Penumbra, Inc.
    • phenox GmbH
    • Stryker Corporation
    • Vesalio LLC

To request Table of Contents and Sample Pages of this report:

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]



    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com